Last reviewed · How we verify
Raclopride C11
Raclopride C11 is a dopamine D2/D3 receptor antagonist labeled with carbon-11 for use as a positron emission tomography (PET) imaging agent.
Raclopride C11 is a dopamine D2/D3 receptor antagonist labeled with carbon-11 for use as a positron emission tomography (PET) imaging agent. Used for PET imaging of dopamine D2/D3 receptor density in the brain for research and diagnostic purposes.
At a glance
| Generic name | Raclopride C11 |
|---|---|
| Also known as | [C11]Raclopride |
| Sponsor | University of North Carolina, Chapel Hill |
| Drug class | Dopamine D2/D3 receptor antagonist (PET imaging agent) |
| Target | Dopamine D2 receptor, Dopamine D3 receptor |
| Modality | Small molecule |
| Therapeutic area | Neurology, Psychiatry, Diagnostic Imaging |
| Phase | FDA-approved |
Mechanism of action
Raclopride C11 binds competitively to dopamine D2 and D3 receptors in the brain and is labeled with the radioactive isotope carbon-11, allowing visualization and quantification of dopamine receptor density and occupancy via PET imaging. It is used as a diagnostic tool to assess dopaminergic neurotransmission in research and clinical settings, particularly in neuropsychiatric and neurodegenerative disorders.
Approved indications
- PET imaging of dopamine D2/D3 receptor density in the brain for research and diagnostic purposes
Common side effects
Key clinical trials
- Brain Dopaminergic Signaling in Opioid Use Disorders (EARLY_PHASE1)
- A Multimodal Imaging Study of Dopamine in Early Psychosis (PHASE1)
- PET-MRI of Reward System in Parkinson's Disease With RBD (NA)
- Neural Basis of Decision-Making Deficits in Traumatic Brain Injury (PHASE1)
- Examining the Effects of Estradiol on Neural and Molecular Response to Reward (PHASE4)
- PET Study to Evaluate Brain Receptor Occupancy, Safety and Pharmacokinetics of ITI-1284 in Healthy Subjects (PHASE1)
- Dopaminergic Modulation of Brain Activation Using Simultaneous PET/Pharmacological MRI (PHASE1)
- Raclopride-PET/MRT (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Raclopride C11 CI brief — competitive landscape report
- Raclopride C11 updates RSS · CI watch RSS
- University of North Carolina, Chapel Hill portfolio CI